Clinical Trials Logo

Resectable Prancreas Carcinoma clinical trials

View clinical trials related to Resectable Prancreas Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02172976 Completed - Clinical trials for Resectable Prancreas Carcinoma

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Start date: November 2014
Phase: Phase 2/Phase 3
Study type: Interventional

In this multicenter study, patients with resectable pancreatic carcinoma will be treated with (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles FOLFIRINOX followed by surgery followed by 4-6 cycles FOLFIRINOX. The overall survival between both therapies will be compared as well as other parameters.